Dr. Justin Lee

Episode #92

Interventional Radiologist Justin Lee tells us about his approach to treatment of Hepatocellular Carcinoma (HCC), including how this has changed over his years in private practice. This is part two of a two part series.

Episode #91

Interventional Radiologist Justin Lee tells us how he started from scratch in growing a robust Interventional Oncology program in private practice, including pitfalls to avoid. This is part one of a two part series.

Episode #20

Our 20th BackTable podcast episode featuring special guests Dr. Justin Lee of Florida Interventional Specialists, and Dr. Terence Gade of Hospital of University of Pennsylvania. They discuss experiences and utility of pressure-directed, antireflux infusion for TACE treatments.

Effective drug delivery systems attempt to maximize homogeneous distribution of the respective agent to the entire tumor to induce cytotoxicity and tumor necrosis. Dr. Justin Lee and Dr. Terence Gade discuss how pressure-directed therapy improves drug delivery to areas of tumor burden in cases of HCC.

For the treatment of HCC, it is important to know the differences between DEB-TACE vs conventional TACE. Lipiodol-based conventional transarterial chemoembolization (cTACE) and drug-eluting bead transarterial chemoembolization (DEB-TACE) are two treatment options for intermediate-stage HCC.

Transarterial chemoembolization (TACE) and radioembolization (Y90) have individualized roles in the treatment of hepatocellular carcinoma. Dr. Justin Lee and Dr. Terence Gade discuss which patients are best suited for TACE versus Y90, as well as the advantages and disadvantages for each intervention.